NEW YORK — Diagnostic testing services provider Maverick Health said on Friday that it has signed an agreement to offer Visby Medical's rapid point-of-care SARS-CoV-2 test.
The Visby Medical COVID-19 Point of Care Test is a single-use, fully integrated RT-PCR assay designed to detect SARS-CoV-2 nucleic acid, providing results within 30 minutes. It received Emergency Use Authorization from the US Food and Drug Administration in February for use with nasopharyngeal, anterior nasal, or mid-turbinate swabs collected by a health care provider or in anterior nasal or mid-turbinate swabs self-collected under the supervision of a healthcare provider.
Under the terms of the agreement, Miami-based Maverick will provide the test to organizational partners, through its network of concierge testing sites in New York, Boston and Miami, and to customers for use at home.
Additional terms were not disclosed.